. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Am J Kidney Dis. 2015 Jul 7;66(4):677–688. doi: 10.1053/j.ajkd.2015.05.019

Table 2.

Number of events, follow-up time, incidence rates, and hazard ratios for all study outcomes based on an inverse probability of treatment weighted population of approximately 15% warfarin users and 85% non-users using full cohort of 12,284 hemodialysis patients.

Outcome	Analysis	Exposure group	No. of events	Follow-up, y^*		IR, per 100 person-y	HR (95% CI)
All-cause mortality	ITT	Warfarin	832	1.34 ± 1.10; 1.01		33.0	1.01 (0.92-1.11)
		No warfarin	4595	1.35 ± 1.14	1.01	32.5
	AT60^a	Warfarin	375	0.60 ± 0.63	0.36	31.7	0.84 (0.73-0.97)
		No warfarin	4005	1.19 ± 1.11	0.84	32.1
Cardiovascular mortality	ITT	Warfarin	349	1.34 ± 1.10	1.01	13.8	1.00 (0.86-1.17)
		No warfarin	1940	1.35 ± 1.14	1.01	13.7
	AT60^a	Warfarin	184	0.60 ± 0.65	0.36	15.6	0.87 (0.70-1.07)
		No warfarin	2071	1.22 ± 1.13	0.85	16.4
Ischemic stroke	ITT	Warfarin	63	1.42 ± 1.19	1.07	2.3	0.68 (0.47-0.99)
		No warfarin	503	1.40 ± 1.21	1.01	3.4
	AT60^a	Warfarin	32	0.61 ± 0.67	0.36	2.7	0.73 (0.44-1.20)
		No warfarin	497	1.30 ± 1.20	0.89	3.7
Hemorrhagic stroke	ITT	Warfarin	29	1.46 ± 1.20	1.09	1.0	0.82 (0.37-1.81)
		No warfarin	192	1.44 ± 1.23	1.05	1.3
	AT60^a	Warfarin	26	0.61 ± 0.68	0.35	2.1	1.92 (0.82-4.48)
		No warfarin	172	1.34 ± 1.23	0.94	1.2
Any stroke or stroke death	ITT	Warfarin	116	1.40 ± 1.17	1.06	4.4	0.83 (0.61-1.12)
		No warfarin	765	1.38 ± 1.19	1.00	5.3
	AT60^a	Warfarin	61	0.65 ± 0.69	0.40	5.0	0.87 (0.57-1.32)
		No warfarin	650	1.19 ± 1.12	0.80	5.2
Gastrointestinal bleeding	ITT	Warfarin	153	1.36 ± 1.15	0.97	5.9	1.00 (0.69-1.44)
		No warfarin	833	1.36 ± 1.19	0.98	5.9
	AT60^a	Warfarin	108	0.60 ± 0.65	0.34	9.0	1.36 (0.89-2.07)
		No warfarin	782	1.25 ± 1.18	0.86	6.0
Composite outcome^b	ITT	Warfarin	890	1.23 ± 1.06	0.91	38.8	1.01 (0.93-1.11)
		No warfarin	4961	1.25 ± 1.10	0.91	38.1
	AT^a	Warfarin	427	0.61 ± 0.65	0.37	37.7	0.89 (0.78-1.02)
		No warfarin	4219	1.08 ± 1.03	0.75	37.1

AT60 – as-treated analysis where patients were censored 60 days after their drug supply ran out; CI – confidence interval, HR, hazard ratio; ITT – intention to treat,

Values given as mean ± standard deviation; median.

Stratified Cox by year when atrial fibrillation was diagnosed.

Composite outcome includes any stroke or stroke death, gastrointestinal bleeding, and all-cause mortality.